Table 1.
Baseline patient demographics
| SC abatacept (n=15) | SC adalimumab (n=15) | |
|---|---|---|
|
| ||
| Age, years | 42.5 (15.4) | 47.7 (10.5) |
|
| ||
| Female, % | 12 (80.0) | 11 (73.3) |
|
| ||
| White, % | 13 (86.7) | 12 (80.0) |
|
| ||
| BMI, kg/m2 | 27.3 (4.5) | 29.5 (4.5) |
|
| ||
| Disease duration, years | 1.4 (1.1) | 1.8 (1.4) |
|
| ||
| TJC | 20.3 (12.5) | 29.3 (16.9) |
|
| ||
| SJC | 13.7 (11.2) | 14.7 (14.4) |
|
| ||
| PGA | 52.1 (29.9) | 57.8 (16.3) |
|
| ||
| CRP, mg/dl | 1.7 (2.4) | 0.7 (0.8) |
|
| ||
| DAS28 (CRP) | 5.0 (1.0) | 5.2 (0.8) |
|
| ||
| History of CV disease, % | 1 (6.7) | 0 |
|
| ||
| History of hypertension, % | 4 (26.7) | 6 (40.0) |
|
| ||
| Smoking history, % | 0 | 4 (26.7) |
|
| ||
| Diabetes, % | 2 (13.3) | 1 (6.7) |
|
| ||
| Statin/other cholesterol-lowering therapy, % | 2 (13.3) | 1 (6.7) |
|
| ||
| Oral steroid use, % | 7 (46.7) | 7 (46.7) |
|
| ||
| Smoking status, % | 0 | 2 (13.3) |
|
| ||
| NSAIDs use, % | 9 (60.0) | 10 (66.7) |
|
| ||
| Aspirin use, % | 2 (13.3) | 3 (20.0) |
|
| ||
| Folic acid use, % | 13 (86.7) | 13 (86.7) |
|
| ||
| HDL anti-oxidant function | ||
|
| ||
| Proinflammatory HDL, % | 5 (33.3) | 5 (33.3) |
| Anti-inflammatory HDL, % | 10 (66.7) | 10 (66.7) |
|
| ||
| HDL inflammatory index (HII) | 1.1 (1.5) | 0.8 (0.6) |
|
| ||
| Total cholesterol, mg/dL | 172.8 (45.7) | 195.3 (37.4) |
|
| ||
| HDL cholesterol (HDL-C), mg/dL | 49.7 (15.0) | 50.0 (13.6) |
|
| ||
| LDL cholesterol (calculated), mg/dL | 93.8 (30.0) | 117.5 (34.7) |
|
| ||
| Triglycerides, mg/dL | 146.9 (84.5) | 139.5 (67.0) |
|
| ||
| Homocysteine, μmol/L | 8.72 (2.97) | 10.17 (3.91) |
Values are mean (SD) unless otherwise stated.
BMI= body mass index; TJC= tender joint count; SJC= swollen joint count; PGA=physician global assessment; CRP= C-reactive protein; DAS28= disease activity scale using a 28 joint count; CV=cardiovascular; HDL=high density lipoprotein; LDL=low density lipoprotein.